Literature DB >> 19904616

Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum.

George Orphanos1, Alexandros Ardavanis.   

Abstract

Leptomeningeal metastases from solid tumors are relatively uncommon events with dismal prognosis. They can be seen mainly in patients with breast and lung cancer, and malignant melanoma, but have also been described in a variety of other tumor types. Leptomeningeal carcinomatosis from prostate cancer is an extremely rare complication, but as patients' survival is prolonged due to more effective treatments, it is expected that more patients will present with leptomeningeal involvement in advanced stages of the disease. In these cases high levels of prostate-specific antigen can be found in the cerebrospinal fluid. This comprehensive review presents the recent findings from the literature.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19904616     DOI: 10.1007/s10585-009-9298-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  35 in total

1.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.

Authors:  C S Straathof; H G de Bruin; D W Dippel; C J Vecht
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

2.  THE FUNCTION OF THE VERTEBRAL VEINS AND THEIR ROLE IN THE SPREAD OF METASTASES.

Authors:  O V Batson
Journal:  Ann Surg       Date:  1940-07       Impact factor: 12.969

3.  Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.

Authors:  M D Galsky; K Simon; G Sonpavde; T E Hutson; M Fleming; G V Kondagunta; W Berry
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

Review 4.  Metastasizing extraneural tumors along the CSF pathway.

Authors:  J Y Lee; M Bergmann; K Kuchelmeister; S Patt; R I Ernestus
Journal:  Clin Neuropathol       Date:  1997 May-Jun       Impact factor: 1.368

Review 5.  Neurologic complications of prostate cancer.

Authors:  Ramsis Benjamin
Journal:  Am Fam Physician       Date:  2002-05-01       Impact factor: 3.292

Review 6.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

7.  Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.

Authors:  C Serrate; Y Loriot; T De La Motte Rouge; M Gross-Goupil; C Massard; B Escudier; A Bossi; K Fizazi
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

8.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.

Authors:  Dominik R Berthold; Gregory R Pond; Freidele Soban; Ronald de Wit; Mario Eisenberger; Ian F Tannock
Journal:  J Clin Oncol       Date:  2008-01-10       Impact factor: 44.544

9.  Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.

Authors:  S L Turner; S Gruenewald; N Spry; V Gebski
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

Review 10.  Prostate-specific antigen in the cerebrospinal fluid leads to diagnosis of solitary cauda equina metastasis: a unique case report and review of the literature.

Authors:  B Schaller; A Merlo; E Kirsch; K Lehmann; P R Huber; P Lyrer; A J Steck; O Gratzl
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  9 in total

1.  Durable remission of leptomeningeal metastases from hormone-responsive prostate cancer.

Authors:  Meng Zhang; Ali Mahta; Ryan Y Kim; Serra Akar; Santosh Kesari
Journal:  Med Oncol       Date:  2011-03-20       Impact factor: 3.064

Review 2.  Biology and therapy of neoplastic meningitis.

Authors:  Aaron G Mammoser; Morris D Groves
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

3.  Leptomeningeal metastases from genitourinary cancer: the University of Texas MD Anderson Cancer Center experience.

Authors:  Shlomit Yust-Katz; Samuel Mathis; Morris D Groves
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

Review 4.  Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer.

Authors:  Eliane Gouvêa de Oliveira Barros; Nathalia Meireles Da Costa; Celia Yelimar Palmero; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti; Antonio Palumbo
Journal:  World J Urol       Date:  2018-07-06       Impact factor: 4.226

5.  Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.

Authors:  Jee Min Lee; Urvi N Mehta; Ly H Dsouza; Beverly Ashleigh Guadagnolo; Deborah L Sanders; Kevin B Kim
Journal:  Melanoma Res       Date:  2013-04       Impact factor: 3.599

6.  Risk factors for leptomeningeal carcinomatosis in patients with brain metastases who have previously undergone stereotactic radiosurgery.

Authors:  Andrew J Huang; Karen E Huang; Brandi R Page; Diandra N Ayala-Peacock; John T Lucas; Glenn J Lesser; Adrian W Laxton; Stephen B Tatter; Michael D Chan
Journal:  J Neurooncol       Date:  2014-07-22       Impact factor: 4.130

7.  Rare Paravertebral and Skull Base Metastases in Prostate Cancer.

Authors:  Gbeminiyi Samuel; Amir Isbell; Onyekachi Ogbonna; Hasan Iftikhar; Susmita Sakruti; Adebayo Atanda; Raj P Manchandani
Journal:  Case Rep Oncol       Date:  2016-11-14

8.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2013-05-02

9.  A case report of prostate cancer with leptomeningeal metastasis.

Authors:  Mansoureh Dehghani; Babak PeyroShabany; Ramin Shahraini; Danial Fazilat-Panah; Fateme Hashemi; James S Welsh; Seyed Alireza Javadinia
Journal:  Cancer Rep (Hoboken)       Date:  2021-06-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.